Compare StocksABT vs CL

Abbott Laboratories (ABT) vs Colgate-Palmolive Company (CL): Which Is the Better Buy in 2026?

As of 2026-06-19, ABT is fairly valued at $88, with a DCF intrinsic value of $93 and a margin of safety of 5%. CL is overvalued at $89, with an intrinsic value of $45 and a margin of safety of -98%. Of the two, ABT has the wider margin of safety.

ABT
Abbott Laboratories
$88.41
VS
CL
Colgate-Palmolive Company
$89.48

Rewards

ABT
  • Abbott Laboratories scores 86/100 on the Economic Moat Score (Wide Moat), with margin stability as the strongest competitive dimension.
  • Insiders have bought $1.1M worth of stock in the past 3 months — significant skin in the game.
  • Altman Z-Score of 5.60 indicates very low bankruptcy risk — the company is firmly in the safe zone.
CL
  • Colgate-Palmolive Company has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • Gross margin of 60.1% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Colgate-Palmolive Company scores 98/100 on the Economic Moat Score (Wide Moat), with roic consistency as the strongest competitive dimension.

Risks

ABT
    CL
    • High leverage (13.49x net debt/equity) combined with thin interest coverage (-1.0x) poses financial risk.
    • 10 insider sales with no purchases over the past 12 months — a persistent pattern of insider selling.

    Key Valuation Metrics

    Learn more →
    ABT
    CL
    Valuation
    $6.34B
    Free Cash Flow
    $3.32B
    4.12%
    FCF Yield
    4.64%
    24.76
    Trailing P/E
    34.68
    14.59
    Forward P/E
    22.13
    Quality & Moat
    5.53%
    ROIC
    40.64%
    12.33%
    ROE
    363.58%
    56.50%
    Gross Margin
    60.06%
    1.34
    PEG Ratio
    1.62
    Balance Sheet Safety
    0.51
    Net Debt / Equity
    13.49
    N/A
    Interest Coverage
    N/A
    2.29
    Net Debt / EBITDA
    1.33
    2.76%
    Dividend Yield
    2.30%
    ABT: 6Ties: 1CL: 5
    ABTCL

    Historical Fundamentals

    Learn more →
    ABT

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    CL

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    ABT
    $1.89
    created per $1 retained over 3 years
    Value Creator
    Σ Retained
    $14.14B
    Δ Market Cap
    +$26.79B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    CL
    $-1.07
    created per $1 retained over 3 years
    Market Cap Declined
    Σ Retained
    $1.96B
    Δ Market Cap
    $-2.10B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    ABT
    4.8% Margin of Safety
    Price is 4.8% below estimated fair value
    Current Price: $88.41
    Fair Value: $92.91
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    CL
    98.0% Overvalued
    Price is 98.0% above estimated fair value
    Current Price: $89.48
    Fair Value: $45.20
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    ABT

    What growth rate is the market pricing in at $88?

    +10.3%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +12.5%

    The market implies +10.3% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +12.5%, reflecting heavy growth investment.

    CL

    What growth rate is the market pricing in at $89?

    +15.5%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +9.9%

    The market implies +15.5% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +9.9%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    ABT
    86/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Margin Stability is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    CL
    98/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. ROIC Consistency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    ABT
    -2.48
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    CL
    -3.00
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    ABT
    Insiders 0.5%Institutions 82.7%Retail & Other 16.8%
    No. of Institutional Holders3,953
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    CL
    Insiders 0.1%Institutions 88.1%Retail & Other 11.8%
    No. of Institutional Holders2,617
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    ABT
    2
    Buys (3M)
    4
    Buys (12M)
    Total value (12M): $4.23M
    STARKS DANIEL J
    Director
    $926,537
    @ $92.65 · 2026-04-27
    BOUDREAU PHILIP P
    Chief Financial Officer
    $201,300
    @ $91.50 · 2026-04-23
    STARKS DANIEL J
    Director
    $1.09M
    @ $108.73 · 2026-02-04
    FORD ROBERT B.
    Chief Executive Officer
    $2.01M
    @ $107.13 · 2026-01-23
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    CL
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    ABT
    0
    Sells (3M)
    8
    Sells (12M)
    Total value (12M): $1.44M
    SALVADORI DANIEL GESUA SIVE
    Officer
    $102,288
    @ $115.58 · 2026-03-02
    MCCOY JOHN A. JR
    Officer
    $67,614
    @ $115.58 · 2026-03-02
    MORRONE LOUIS H
    Officer
    $132,224
    @ $115.58 · 2026-03-02
    SHROFF ERIC
    Officer
    $81,946
    @ $115.58 · 2026-03-02
    CUSHMAN ELIZABETH C
    General Counsel
    $30,398
    @ $115.58 · 2026-03-02
    MORELAND MARY K
    Officer
    $70,851
    @ $115.58 · 2026-03-02
    SHROFF ERIC
    Officer
    $203,043
    @ $128.02 · 2025-11-25
    BOUDREAU PHILIP P
    Chief Financial Officer
    $746,758
    @ $134.55 · 2025-08-08
    BLOUNT SALLY E
    Director
    $337,116
    @ $129.66 · 2025-04-30
    EARNHARDT LISA D
    President
    $12.23M
    @ $133.83 · 2025-03-07
    MCCOY JOHN A. JR
    Officer
    $77,652
    @ $138.17 · 2025-03-03
    SHROFF ERIC
    Officer
    $77,652
    @ $138.17 · 2025-03-03
    MORELAND MARY K
    Officer
    $109,292
    @ $138.17 · 2025-03-03
    MORRONE LOUIS H
    Officer
    $153,507
    @ $138.17 · 2025-03-03
    WAINER ANDREA F
    Officer
    $131,123
    @ $138.17 · 2025-03-03
    FORD ROBERT B.
    Chief Executive Officer
    $37.44M
    @ $131.17 · 2025-02-05
    SALVADORI DANIEL GESUA SIVE
    Officer
    $3.05M
    @ $128.50 · 2025-01-30
    ALLEN HUBERT L.
    Officer
    $24.34M
    @ $128.26 · 2025-01-30
    ALLEN HUBERT L.
    Officer
    $18.42M
    @ $117.04 · 2024-10-21
    FORD ROBERT B.
    Chief Executive Officer
    $16.49M
    @ $116.41 · 2024-09-12
    MCCOY JOHN A. JR
    Officer
    $3,100
    @ $114.81 · 2024-09-04
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    CL
    2
    Sells (3M)
    10
    Sells (12M)
    Total value (12M): $26.11M
    MALCOLM GREGORY
    Officer
    $203,412
    @ $88.44 · 2026-05-15
    MASSEY SALLY
    Officer
    $751,633
    @ $87.41 · 2026-05-07
    TSOURAPAS PANAGIOTIS
    Officer
    $4.78M
    @ $95.57 · 2026-02-12
    HAZLIN JOHN
    Officer
    $1.98M
    @ $94.25 · 2026-02-10
    MALCOLM GREGORY
    Officer
    $1.21M
    @ $94.91 · 2026-02-06
    MASSEY SALLY
    Officer
    $1.51M
    @ $95.03 · 2026-02-05
    WALLACE NOEL R
    Chief Executive Officer
    $4.28M
    @ $93.91 · 2026-02-04
    DANIELS JENNIFER M.
    Officer
    $2.08M
    @ $94.34 · 2026-02-04
    SUTULA STANLEY J III
    Chief Financial Officer
    $9.22M
    @ $94.27 · 2026-02-04
    MASSEY SALLY
    Officer
    $100,061
    @ $80.89 · 2025-11-21
    MASSEY SALLY
    Officer
    $200,183
    @ $88.97 · 2025-05-15
    MASSEY SALLY
    Officer
    $736,152
    @ $92.02 · 2025-02-25
    MALCOLM GREGORY
    Officer
    $101,121
    @ $95.94 · 2024-11-26
    WALLACE NOEL R
    Chief Executive Officer
    $3.17M
    @ $95.00 · 2024-11-22
    SUTULA STANLEY J III
    Chief Financial Officer
    $4.27M
    @ $94.11 · 2024-11-05
    SUTULA STANLEY J III
    Chief Financial Officer
    $4.68M
    @ $93.53 · 2024-11-01
    HUND-MEJEAN MARTINA
    Director
    $240,228
    @ $103.86 · 2024-08-23
    DANIELS JENNIFER M.
    Officer
    $2.26M
    @ $102.76 · 2024-08-08
    TSOURAPAS PANAGIOTIS
    Officer
    $1.52M
    @ $102.94 · 2024-08-08
    KOOYMAN JOHN W
    Officer
    $2.55M
    @ $102.88 · 2024-08-06
    MASSEY SALLY
    Officer
    $1.64M
    @ $103.28 · 2024-08-06
    MALCOLM GREGORY
    Officer
    $1.09M
    @ $103.10 · 2024-08-06
    TSOURAPAS PANAGIOTIS
    Officer
    $3.98M
    @ $99.47 · 2024-07-31
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    ABT
    FearGreed
    😐Neutral(41/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    CL
    FearGreed
    😐Neutral(55/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    ABT
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (41)
    CL
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (55)
    View ABT Full AnalysisView CL Full Analysis

    Frequently Asked Questions: ABT vs CL

    Is Abbott Laboratories or Colgate-Palmolive Company more undervalued in 2026?

    Based on our discounted cash flow model, ABT trades at a 4.8% margin of safety (intrinsic value $93 vs. price $88), compared to CL's -98.0% margin of safety (intrinsic $45 vs. $89).

    Which stock has a wider economic moat, Abbott Laboratories or Colgate-Palmolive Company?

    CL scores 98/100 (Wide moat), while ABT scores 86/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Which company has better free cash flow, Abbott Laboratories or Colgate-Palmolive Company?

    Colgate-Palmolive Company (CL) generates a 4.6% free cash flow yield, compared to Abbott Laboratories's 4.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Abbott Laboratories or Colgate-Palmolive Company?

    CL earns 40.6% ROIC versus ABT's 5.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Which dividend is safer, Abbott Laboratories's or Colgate-Palmolive Company's?

    ABT's dividend earns a safety score of 84/100 (Very Safe), compared to CL's 64/100 (Safe). ABT has raised its dividend for 3 consecutive years.

    ABT vs CL: Which Is the Better Buy in 2026? | SafetyMargin.io